Package Types for Different Dosage Forms

Taneja, Neha; Deb, Pran Kishore; Maheshwari, Rahul; Tekade, Rakesh K.

doi:10.1016/b978-0-12-814421-3.00016-6

Cited by 4 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We designed and developed the XTEMP-R device (described elsewhere). 15 The device comprises a flexible receptacle or tube, a tight-fitting cap, and a suction cup base ( Figure 1 ). The soft walls of the device are made of biocompatible, low-hardness, high-consistency silicone rubber (Wacker Chemie, Munich, Germany).…”

Section: Methodsmentioning

confidence: 99%

A novel home-based method for preparing suspensions of anti-TB drugs

Taneja,

Nahata,

Scarim

et al. 2023

int j tuberc lung dis

View full text Add to dashboard Cite

BACKGROUND: Tablets are the most widely available dosage form for the treatment of TB; however, adult tablets fail to meet the needs of young children who cannot swallow these tablets or require dose titration. We tested a new, simple device (XTEMP-R®) and the methodology for converting tablets of TB drugs into a homogeneous suspension for home use by children and caregivers.METHODS: XTEMP-R is a new device used for converting tablets into liquid preparations. Four TB drugs – pretomanid, delamanid, clofazimine and bedaquiline – were dispersed in the device utilizing water and simple syrup. The reproducibility of accurately delivering aliquots from the suspension upon preparation and upon redispersion after storing for 2 days was studied.RESULTS: Suspensions of each of the drugs tested were easily prepared in about 10 min and were visually uniform in consistency. Dosages in 2 and 5 mL were assessed in suspension, and those in 5 mL tested upon redispersion after 2 days. The observed range for these dosages spanned from 94.6% to 101.1% of the theoretical concentration for the suspensions under examination. The cleaned device had no detectable residual drug.CONCLUSION: XTEMP-R can be used at home by caregivers to prepare doses of suspensions accurately for children and patients who cannot swallow tablets.

show abstract

Section: Methodsmentioning

confidence: 99%

A novel home-based method for preparing suspensions of anti-TB drugs

Taneja,

Nahata,

Scarim

et al. 2023

int j tuberc lung dis

View full text Add to dashboard Cite

show abstract

“…Dalam melaksanakan regulasi tersebut, PT. Otsuka Indonesia mengambil langkah untuk mengganti material bahan kemas dari penggunaan material kemas primer plastik LDPE menjadi LDPP yang dinilai memiliki ketahanan lebih baik dalam mempertahankan stabilitas dan nilai sterilitas pada produk yang terkandung di dalamnya [5], [6].…”

Section: Pendahuluanunclassified

Analisis Fmea Untuk Pengambilan Keputusan Modifikasi Punch Unit Mesin Bp-321

Saraswati,

Rosiarto,

Wulan

et al. 2023

Distilat: J. Tekn. Sep

View full text Add to dashboard Cite

PT Otsuka Indonesia merupakan perusahaan asing dibidang industri farmasi, dengan produk utama cairan infus dan obat-obatan terapetik. Cairan infus yang dihasilkan dalam skala kecil biasa disebut dengan SVP (Small Volume Parenteral) dikemas dalam kemasan primer plastik berbentuk ampul dengan volume 10 – 25 ml. Pembuatan cairan dan wadah ampul melalui beberapa tahapan proses seperti persiapan dan pengadukan, blow-fill-seal (BFS), pengemasan, dan penyimpanan. Seiring perjalanan waktu, standar regulasi pembuatan produk ampul semakin berkembang, salah satunya adalah penggantian material kemas primer dari LDPE (Low Density Polyethylene) menjadi LDPP (Low Density Polypropylene) yang dinilai mampu menjaga nilai stabilitas dan sterilitas produk. Produksi ampul menggunakan mesin BP-321 pada proses BFS dengan punch unit lama hanya bisa memotong ampul bermaterial LDPE, namun tidak bisa memotong LDPP yang lebih keras. Sehingga, perusahaan memodifikasi mesin dengan mengganti punch unit lama dengan external punch unit pada mesin BP-321 untuk proses BFS produksi ampul. Untuk mendukung keputusan tersebut, perusahaan melakukan analisis FMEA (Failure Mode and Effect Analysis) yang memungkinkan industri membuat keputusan diperlukan atau tidaknya penambahan external punch unit. Setelah dilakukan analisis FMEA dengan dengan perolehan Risk Priotity Number sebesar 720,72, maka perlu dilakukan penambahan external punch unit pada mesin BP-321.

show abstract

“…In general, packaging at the producer level is divided into 3, namely primary, secondary, and tertiary ( Ortiz et al, 2020 , Ramakanth et al, 2021 ). Manufacturers produce vaccines and diluents for reconstituted products in primary packaging, which are then stored in secondary containers in the form of cartons ( Vaccine Presentation and Packaging Advisory Group, 2015 , WHO et al, 2017 , Taneja et al, 2018 ). The several types of primary packaging currently available are shown in Fig.…”

Section: Storage Specification Standard Challengementioning

confidence: 99%

“…2 . Furthermore, the secondary packaging is repackaged in a larger carton known as a “tertiary carton” ( Ortiz et al, 2020 , Vaccine Presentation and Packaging Advisory Group, 2015 , Taneja et al, 2018 ) (see Fig. 3 ).…”

Section: Storage Specification Standard Challengementioning

confidence: 99%

Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs

et al. 2022

View full text Add to dashboard Cite

The outbreaks of infectious diseases that spread across countries have generally existed for centuries. An example is the occurrence of the COVID-19 pandemic in 2020, which led to the loss of lives and economic depreciation. One of the essential ways of handling the spread of viruses is the discovery and administration of vaccines. However, the major challenges of vaccination programs are associated with the vaccine cold chain management and cold storage facilities. This paper discusses how vaccine cold chain management and cold storage technology can address the challenges of vaccination programs. Specifically, it examines different systems for preserving vaccines in either liquid or frozen form to help ensure that they are not damaged during distribution from manufacturing facilities. Furthermore, A vaccine is likely to provide very low efficacy when it is not properly stored. According to preliminary studies, the inability to store vaccine properly is partly due to the incompetency of many stakeholders, especially in technical matters. The novelty of this study is to thoroughly explore cold storage technology for a faster and more comprehensive vaccine distribution hence it is expected to be one of the reference and inspiration for stakeholders.

show abstract

Package Types for Different Dosage Forms

Cited by 4 publications

References 63 publications

A novel home-based method for preparing suspensions of anti-TB drugs

A novel home-based method for preparing suspensions of anti-TB drugs

Analisis Fmea Untuk Pengambilan Keputusan Modifikasi Punch Unit Mesin Bp-321

Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs

Contact Info

Product

Resources

About